Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, and antiviral activities

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 4, 2001, Pages 1086-1093

  Zhang, K E ^a   Wu, E ^a   Patick, A K ^a   Kerr, B ^a   Zorbas, M ^a   Lankford, A ^a   Kobayashi, T ^a   Maeda, Y ^a   Shetty, B ^a   Webber, S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHOXY 4 HYDROXYNELFINAVIR; DRUG METABOLITE; HYDROXY TERT BUTYLAMIDE; NELFINAVIR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

BLOOD PROTEINS; CELL LINE; CHROMATOGRAPHY, LIQUID; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; KINETICS; MALE; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TESTS; NELFINAVIR;

EID: 0035086498     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.4.1086-1093.2001     Document Type: Article

References (28)

1. Feasibility of drug screening with panels of human tumor cell lines using microculture tetrazolium assay
2. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans
3. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations
4. Saquinavir: An HIV protease inhibitor
5. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society - USA Panel
6. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society - USA Panel
7. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A4
8. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
9. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs and humans
10. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism
11. HIV-protease inhibitors
12. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
13. Indinavir: A pharmacologic and clinical review of a new HIV protease inhibitor
14. 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors
15. Ritonavir
16. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
17. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: Results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus
18. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
19. Recovery of the immune system with antiretroviral therapy: The end of opportunism?
20. Development of HIV protease inhibitors: A survey
21. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes
22. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy
23. Saquinavir. Clinical pharmacology and efficacy
24. Antiretroviral therapy for HIV infection: Promises and problems
25. Metabolite pharmacokinetics
26. Cytochrome P450 isoforms involved in the metabolism of nelfinavir mesylate, an HIV-1 protease inhibitor
27. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma
28. Biotransformation of nelfinavir, a potent HIV protease inhibitor, in healthy human subjects